Pharmacotherapeutic strategies for treating hypertension in patients with obesity

References

• Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013;15:14–33.
   Google Scholar
• Pickering G. High blood pressure. New York, NY: Grune and Stratton, Inc.; 1968.
   Google Scholar
• Kannel WB, Brand N, Skinner JJ, et al. The relation of adiposity to blood pressure and development of hypertension. Framingham Study Ann Intern Med. 1967;67:48–59.
   PubMed Web of Science ®Google Scholar
• Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44:12–19.
   PubMed Web of Science ®Google Scholar
• Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378–1384.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393–404.
   PubMedGoogle Scholar
• Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594–599.
   PubMed Web of Science ®Google Scholar
• Rocchini AP. Cardiovascular regulation in obesity-induced hypertension. Hypertension. 1992;19:I5660.
   Web of Science ®Google Scholar
• Carnagarin R, Gregory C, Azzam O, et al. The role of sympatho-inhibition in combination treatment of obesity-related hypertension. Curr Hypertens Rep. 2017;19:99.
   PubMed Web of Science ®Google Scholar
• Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:75–88.
   PubMedGoogle Scholar
• Sharma AM, Rossner S. Who cares about the obese hypertensive patient? J Intern Med. 2002;251:369–371.
   PubMed Web of Science ®Google Scholar
• Engeli S, Sharma AM. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol. 2002;17:355–359.
   PubMed Web of Science ®Google Scholar
• WHO Consultation on Obesity (1999: Geneva, Switzerland) & World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. (WHO technical report series). Geneva: World Health Organization; 2000. Available from: https://www.who.int/iris/handle/10665/42330.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Lambert E, Straznicky N, Schlaich M, et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50:862–868.
   PubMed Web of Science ®Google Scholar
• Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61:1081–1090.
   PubMedGoogle Scholar
• Esler M, Straznicky N, Eikelis N, et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48:787–796.
   PubMed Web of Science ®Google Scholar
• Rumantir MS, Vaz M, Jennings GL, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–1133.
   PubMed Web of Science ®Google Scholar
• Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583.
   PubMed Web of Science ®Google Scholar
• Wofford MR, Anderson DC Jr, Brown CA, et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14:694–698.
   PubMed Web of Science ®Google Scholar
• Shibao C, Gamboa A, Diedrich A, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49:27–33.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Colombo M, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 1998;97:2037–2042.
   Google Scholar
• Ebbert JO, Elrashidi MY, Jensen MD. Managing overweight and obesity in adults to reduce cardiovascular disease risk. Curr Atheroscler Rep. 2014;16:445.
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Redon J, et al. European society of hypertension working group on obesity: background, aims and perspectives. J Hypertens. 2007;25:897–900.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–2693.
   PubMed Web of Science ®Google Scholar
• Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;5:1035–1041.
   Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115:2761–2788.
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoffv RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–68.
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens. 2005;23:2313–2318.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Pischon T, Engeli S, et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19:667–674.
   PubMed Web of Science ®Google Scholar
• Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001;38:705–708.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611–616.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145–153.
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25:841–848.
   PubMed Web of Science ®Google Scholar
• Masuo K, Mikami H, Ogihara T, et al. Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients. Am J Hypertens. 1997;10:600–610.
   PubMed Web of Science ®Google Scholar
• Masuo K, Mikami H, Ogihara T, et al. Weight reduction and pharmacological treatment in obese hypertensives. Am J Hypertens. 2001;14:530–538.
   PubMed Web of Science ®Google Scholar
• Shammas NW, Sica DA, Toth PP. A guide to the management of blood pressure in the diabetic hypertensive patients. Am J Cardio Vasc Drugs. 2009;9:149–162.
   PubMed Web of Science ®Google Scholar
• Perret-Guillaume C, Joly L, Jankowski P, et al. Benefits of the RAS blockade: clinical evidence before the ONTARGET study. J Hypertens. 2009;279:S53–S57.
   Google Scholar
• Grassi G, Mancia G. Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trials. J Hypertens. 2009;27:S40–S44.
   Web of Science ®Google Scholar
• Nishiyama A, Hitomi H, Rahman A, et al. Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers. J Pharmacol Sci. 2009;109:1–6.
   PubMed Web of Science ®Google Scholar
• Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol. 2003;91:28G–34G.
   PubMed Web of Science ®Google Scholar
• Sleight P, Redon J, Verdecchia P, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endopoint trial study. J Hypertens. 2009;27:1360–1369.
   PubMed Web of Science ®Google Scholar
• Kurtz TW. Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Prac Cardiovasc Med. 2008;5:S19–S26.
   PubMedGoogle Scholar
• Makita S, Abiko A, Naganuma Y, et al. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism. 2008;57:1473–1478.
   PubMed Web of Science ®Google Scholar
• Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the irbesartan/HCTZ blood pressure reduction in diverse patients populations trial. Clin Ther. 2008;30:2354–2365.
   PubMed Web of Science ®Google Scholar
• Sowers JR, Neutel JM, Saunders E, et al. INCLUSIVE investigators. J Clin Hypertens (Greenwich). 2006;8:470–480.
   PubMedGoogle Scholar
• Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther. 2007;29:1803–1824.
   PubMed Web of Science ®Google Scholar
• Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–1163.
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20.
   PubMed Web of Science ®Google Scholar
• Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–226.
   PubMed Web of Science ®Google Scholar
• Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise,promise, and potential limitations of a new antihypertensive drug. Am J Med. 2008;121:265–271.
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663–1671.
   PubMed Web of Science ®Google Scholar
• Azizi M, Menard J. Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther. 2013;27:145–153.
   PubMed Web of Science ®Google Scholar
• Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin–angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344.
   PubMedGoogle Scholar
• Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt- signaling pathway. Int J Obes (Lond). 2007;31:864–870.
   PubMed Web of Science ®Google Scholar
• Stas S, Whaley-Connell AT, Sowers JR. Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens. 2008;10:94–96.
   Web of Science ®Google Scholar
• Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–930.
   PubMed Web of Science ®Google Scholar
• Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–aldosterone system. J Hypertens. 2010;28:2329–2335.
   PubMedGoogle Scholar
• Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–845.
   PubMed Web of Science ®Google Scholar
• De SF, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147–152.
   PubMed Web of Science ®Google Scholar
• George J, Struthers AD. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin Pharmacother. 2007;8:3053–3059.
   PubMed Web of Science ®Google Scholar
• Hummel D, Raff U, Schwarz TK, et al. Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives. J Nephrol. 2010;23:563–568.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Gatzka C, Schachinger H, et al. Obesity as a determinant for response to antihypertensive treatment. BMJ. 1993;307:537–540.
   PubMedGoogle Scholar
• Stoa-Birketvedt G, Thom E, Aarbakke J, et al. Body fat as a predictor of the antihypertensive effect of nifedipine. J Intern Med. 1995;237:169–173.
   PubMed Web of Science ®Google Scholar
• Prichard BN, Graham BR, Owens CW. Moxonidine: a new antiadrenergic antihypertensive agent. J Hypertens. 1999;17:S41–54.
   Web of Science ®Google Scholar
• Nowak L, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2005;18:1470–1475.
   PubMed Web of Science ®Google Scholar
• Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 1996;27:S49–S54.
   PubMed Web of Science ®Google Scholar
• Sun Z, Ernsberger P. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. J Pharmacol Exp Ther. 2007;320:845–852.
   PubMed Web of Science ®Google Scholar
• Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens. 2013.
   PubMedGoogle Scholar
• Sanjuliani AF, De Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621–629.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18:669–675.
   PubMed Web of Science ®Google Scholar
• Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab. 2006;8:456–465.
   PubMed Web of Science ®Google Scholar
• Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens. 1999;17:S29–S35.
   Web of Science ®Google Scholar
• Strojek K, Grzeszczak W, Górska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12:602–605.
   PubMed Web of Science ®Google Scholar
• Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709–1717.
   PubMedGoogle Scholar
• Topal E, Cikim AS, Cikim K, et al. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs. 2006;6:343–348.
   PubMedGoogle Scholar
• He J, Ogden LG, Vupputuri S, et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999;282:2027–2034.
   PubMed Web of Science ®Google Scholar
• Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) study group. Hypertension. 1997;30:140–145.
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–873.
   PubMed Web of Science ®Google Scholar
• Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension. 1992;19:I67–77.
   PubMed Web of Science ®Google Scholar
• Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8:461–466.
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens. 2009;11:5–10.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA. 2004;292:43–44.
   PubMed Web of Science ®Google Scholar
• Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689–694.
   PubMed Web of Science ®Google Scholar
• Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension. 2009;54:951–953.
   PubMed Web of Science ®Google Scholar
• Kuo S-W, Dee P, Hung Y-J, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens. 2003;16:623–628.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Clemmons DR, Nogami H, et al. Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Kidney Int. 1995;47:818–828.
   PubMed Web of Science ®Google Scholar
• Broekhuysen J, Deger F, Douchamps J, et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31:29–34.
   PubMed Web of Science ®Google Scholar
• Grassi G, Cattaneo BM, Seravalle G, et al. Obesity and the sympathetic nervous system. Blood Press. 1996;1:43–46.
   Google Scholar
• Holman R, Turner R, Stratton I, et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK prospective diabetes study group. BMJ. 1998;317:713–720.
   PubMedGoogle Scholar
• Canzanello VJ, Sheps SG. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: what's new? what's different? Cardiol Rev. 1998;6:272–277.
   Google Scholar
• Dargie HJ, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
   PubMed Web of Science ®Google Scholar
• Morel Y, Gadient A, Keller U, et al. Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. J Cardiovasc Pharmacol. 1995;26:306–311.
   PubMed Web of Science ®Google Scholar
• MacMahon SW, Macdonald GJ, Bernstein L, et al. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet. 1985;1:1233–1236.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–412.
   PubMed Web of Science ®Google Scholar
• Williams B. The obese hypertensive: the weight of evidence against beta-blockers. Circulation. 2007;115:1973–1974.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903–1907.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Pischon T, Hardt S, et al. Hypothesis: betaadrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250–254.
   PubMed Web of Science ®Google Scholar
• Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11:309–315.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Still; pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–362.
   PubMed Web of Science ®Google Scholar
• ALLHAT. Officers and coordinators for the ALLHAT collaborative research group. major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32–41.
   PubMed Web of Science ®Google Scholar
• Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin N Am. 2005;39:69–79.
   Google Scholar
• Igel LI, Kumar RB, Saunders KH, et al. Practical use of pharmacotherapy for obesity. Gastroenterology. 2017;152:1765–1779.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–699.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37:1443–1451.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar